Journey Medical logo

Journey MedicalNASDAQ: DERM

Profile

Sector:

Healthcare

Country:

United States

IPO:

12 November 2021

Next earnings report:

08 August 2024

Last dividends:

N/A

Next dividends:

N/A
$103.07 M
-36%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
92%vs. sector
-52%vs. 3y high
29%vs. sector

Price

after hours | Wed, 03 Jul 2024 20:08:34 GMT
$5.15-$0.08(-1.53%)

Dividend

No data over the past 3 years
$13.03 M$13.88 M
$13.03 M-$10.44 M

Analysts recommendations

Institutional Ownership

DERM Latest News

Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript
Seeking Alpha13 May 2024 Sentiment: POSITIVE

Journey Medical Corporation (NASDAQ: DERM) will be hosting its Q1 2024 Earnings Conference Call on May 14, 2024 at 4:30 PM ET. Presenters include Jaclyn Jaffe, Claude Maraoui, Joseph Benesch, Dr. Srinivas Sidgiddi, and Ramsey Allous. Conference call participants include Scott Henry, Kalpit, and others. Thank you for joining us.

Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript
Seeking Alpha21 March 2024 Sentiment: POSITIVE

Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript

Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
Zacks Investment Research19 March 2024 Sentiment: POSITIVE

Journey Medical (DERM) stock rises as the FDA accepts its regulatory filing for review seeking approval for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults.

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
GlobeNewsWire15 March 2024 Sentiment: NEGATIVE

Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
Zacks Investment Research20 December 2023 Sentiment: POSITIVE

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
Zacks Investment Research13 December 2023 Sentiment: POSITIVE

Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.

Relative Price Strength Makes These 5 Stocks Excellent Buys
Zacks Investment Research11 December 2023 Sentiment: POSITIVE

WING, JAKK, NSIT, GIII and DERM are five stocks with explosive relative price strength.

Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great Choice
Zacks Investment Research30 November 2023 Sentiment: POSITIVE

Does Journey Medical Corporation (DERM) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'
Zacks Investment Research29 November 2023 Sentiment: POSITIVE

Journey Medical Corporation (DERM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Journey Medical Corporation (DERM) Q3 2023 Earnings Call Transcript
Seeking Alpha12 November 2023 Sentiment: POSITIVE

Journey Medical Corporation (NASDAQ:DERM ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Interim Chief Financial Officer Dr. Srinivas Sidgiddi - Vice President, Research and Development Ramsey Allous - General Counsel and Corporate Secretary Conference Call Participants Scott Henry - ROTH Capital Andy Fleszar - B. Riley Operator Ladies and gentlemen, thank you for standing by.

  • 1(current)

What type of business is Journey Medical?

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

What sector is Journey Medical in?

Journey Medical is in the Healthcare sector

What industry is Journey Medical in?

Journey Medical is in the Drug Manufacturers - Specialty & Generic industry

What country is Journey Medical from?

Journey Medical is headquartered in United States

When did Journey Medical go public?

Journey Medical initial public offering (IPO) was on 12 November 2021

What is Journey Medical website?

https://journeymedicalcorp.com

Is Journey Medical in the S&P 500?

No, Journey Medical is not included in the S&P 500 index

Is Journey Medical in the NASDAQ 100?

No, Journey Medical is not included in the NASDAQ 100 index

Is Journey Medical in the Dow Jones?

No, Journey Medical is not included in the Dow Jones index

When does Journey Medical report earnings?

The next expected earnings date for Journey Medical is 08 August 2024